Related Experiment Video
Updated: Jul 4, 2025
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Antiviral treatment standards for hepatitis B: An urgent need for expansion
Zi-Hong Bao1, Zhi-Kun Dai1, Hao-Xian Tang2,3
1Department of Infectious Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong Province, China.
Insights
Chronic hepatitis B (CHB) treatment rates are low due to strict guidelines. Re-evaluating standards and expanding eligibility for antiviral therapy can improve patient outcomes and reduce mortality.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Chronic hepatitis B (CHB) is a significant global health issue.
- Low treatment rates for CHB contribute to substantial liver-related mortality.
- Current treatment criteria are often too stringent, limiting access to care.
Purpose of the Study:
- To advocate for a re-evaluation of current CHB treatment standards.
- To propose expanding antiviral treatment eligibility for hepatitis B virus (HBV)-infected individuals.
- To suggest streamlining CHB diagnosis for improved cost-effectiveness and survival.
Main Methods:
- This is a letter to the editor, referencing a review on long-term hepatitis B virus treatment.
- Discussion based on current understanding of CHB and emerging antiviral agents.
- Analysis of existing treatment guidelines and diagnostic processes.
Main Results:
- Current global treatment rates for CHB are unacceptably low.
- Stringent national guidelines are a key factor limiting treatment access.
- Advances in understanding HBV and new therapies necessitate updated treatment approaches.
Conclusions:
- A new classification system for CHB patients is needed.
- Expanding antiviral treatment eligibility is crucial for improving outcomes.
- Streamlining diagnosis and treatment criteria can enhance cost-effectiveness and survival prospects for HBV patients.
Abstract:
The present letter to the editor is related to the review with the title "Past, present, and future of long-term treatment for hepatitis B virus." Chronic hepatitis B (CHB) represents an important and pressing public health concern. Timely identification and effective antiviral therapy hold the potential to reduce liver-related mortality attributable to chronic infection with hepatitis B virus (HBV) substantially. However, the current global treatment rates for CHB remain conspicuously low, with the excessively stringent treatment criteria advocated by national CHB guidelines being a contributing factor to these low rates. Nevertheless, recent strides in comprehending this malady and the emergence of novel antiviral agents prompt the imperative re-evaluation of treatment standards to extend the sphere of potential beneficiaries. An impending need arises for a novel paradigm for the classification of patients with CHB, the expansion of antiviral treatment eligibility for HBV-infected individuals, and even the streamlining of the diagnostic process for CHB to amplify cost-effectiveness and augment survival prospects.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
